

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU BIOPHARMA CO., LTD.

樂普生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2157)

INSIDE INFORMATION ANNOUNCEMENT GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE

INTRODUCTION

Reference is made to the announcement of the Company dated May 28, 2025 in relation to the issuance of the Filing Notice by the CSRC in respect of the Conversion and Listing (the “**Announcement**”). Unless otherwise stated, terms used herein shall have the same meanings as those defined in the Announcement.

LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE

The Company has applied to the Listing Committee of the Stock Exchange for the approval (the “**Listing Approval**”) of the listing of and the permission to deal in 54,268,364 H shares (the “**Converted H Shares**”), representing the maximum number of unlisted shares to be converted under the Conversion and Listing (the “**Unlisted Shares**”). The Company is pleased to announce that the Listing Approval was granted by the Stock Exchange on June 19, 2025.

SHAREHOLDING STRUCTURE

The Conversion and Listing will involve a total of 4 participating holders of 54,268,364 Unlisted Shares who will, after the Conversion and Listing, hold approximately 3.17% of the total issued shares of the Company.

Set out below is the percentage holding in the Company in relation to the participating shareholders of the Unlisted Shares upon completion of the Conversion and Listing.

Name of the participating shareholders of the Unlisted Shares	Number of Unlisted Shares Converted to H shares	Approximate percentage of total issued share of the Company upon completion of the Conversion and Listing (%)
Kington Capital No. 1 Equity Investment Partnership (Limited Partnership)* (蘇州翼樸一號股權投資合夥企業(有限合夥))	39,436,620	2.31
Suzhou Suzi Investment Limited Partnership* (蘇州蘇梓投資合夥企業(有限合夥))	9,859,155	0.58
Shanghai Healthcare Capital Partnership (Limited Partnership) * (上海生物醫藥產業股權投資基金合夥企業 (有限合夥))	3,654,111	0.21
Mr. Wang Lei (王磊先生)	1,318,478	0.08
Total	<u>54,268,364</u>	<u>3.17</u>

Note: The percentages have been rounded up to two decimal places. Accordingly, the total percentage may not be equal to the apparent total percentage.

Upon completion of the Conversion and Listing, the share capital structure of the Company is as follows:

Class of shares	Immediately before completion of the Conversion and Listing		Upon completion of the Conversion and Listing	
	<i>Number of shares</i>	<i>Approximate percentage %</i>	<i>Number of shares</i>	<i>Approximate percentage %</i>
Unlisted domestic shares	54,268,364	3.17	–	–
H shares	<u>1,656,346,474</u>	<u>96.83</u>	<u>1,710,614,838</u>	<u>100</u>
Total	<u>1,710,614,838</u>	<u>100.00</u>	<u>1,710,614,838</u>	<u>100.00</u>

Note: The percentages have been rounded up to two decimal places. Accordingly, the total percentage may not be equal to the apparent total percentage.

The Company shall complete the relevant conversion and trading procedures in respect of the Converted H Shares and will make further announcement(s) on the progress of the Conversion and Listing in accordance with the requirements of the Listing Rules and applicable laws, as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Lepu Biopharma Co., Ltd.
Dr. Pu Zhongjie
Chairman of the Board and Executive Director

Shanghai, the PRC
June 19, 2025

As at the date of this announcement, the Board comprises Dr. Pu Zhongjie (chairman) and Dr. Sui Ziyue (chief executive officer) as executive Directors; Mr. Yang Hongbing and Ms. Pu Jue, as non-executive Directors; and Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua as independent non-executive Directors.

* *For identification purpose only*